Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Luis Fong

Nurse Practitioner, Psychiatric/Mental Health Phoenix, AZ Nurse Practitioner

NPI 1598259467 CMS profile 11077040

610 E Baseline Rd Ste 5, Phoenix, AZ 85042

Open in the dashboard

General payments

$59,079

368 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luis Fong of Phoenix, AZ is reported in the CMS Open Payments database as having received $59,079 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,855 69
2024 General $6,363 48
2023 General $14,100 49
2022 General $9,500 88
2021 General $22,260 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Fong
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Luis Fong were reported at $6,855. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Luis Fong Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $22,260 $166 $54–$482 $132
2022 $9,500 $195 $66–$559 $149
2023 $14,100 $233 $82–$673 $160
2024 $6,363 $236 $84–$688 $164
2025 $6,855 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $53,972 160 payments
  2. Alkermes, Inc. $1,619 40 payments
  3. ITI, Inc. $1,432 72 payments
  4. Sunovion Pharmaceuticals Inc. $520 28 payments
  5. Otsuka America Pharmaceutical, Inc. $254 13 payments
  6. Janssen Pharmaceuticals, Inc $194 6 payments
  7. Teva Pharmaceuticals USA, Inc. $190 8 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $136 9 payments
  9. Janssen Scientific Affairs, LLC $135 1 payment
  10. Neurocrine Biosciences, Inc. $128 6 payments
  11. Other $498 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,600 40 payments
  2. Food and Beverage $6,574 288 payments
  3. Travel and Lodging $1,813 36 payments
  4. Education $92 4 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $48,093 134 payments
  2. VRAYLAR Neuroscience $5,879 26 payments
  3. LYBALVI Cns $1,121 25 payments
  4. CAPLYTA $1,098 51 payments
  5. LYBALVI Cns $1,009 20 payments
  6. ARISTADA Cns $795 26 payments
  7. ARISTADA Cns $795 26 payments
  8. LYBALVI Cns $752 11 payments
  9. LYBALVI Cns $752 11 payments
  10. ARISTADA INITIO $684 21 payments
  11. Other $3,827 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,003

Median for Nurse Practitioner: 389

Drug cost

$100,718

Median for Nurse Practitioner: $21,885

Branded share of claims

21.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 52 $75,669
Vyvanse Lisdexamfetamine Dimesylate Brand 12 $4,490
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 17 $3,219
Vilazodone Hcl Generic 13 $2,917
Buspirone Hcl Generic 93 $1,704
Bupropion Hcl Sr Bupropion Hcl Brand 58 $1,439
Quetiapine Fumarate Generic 43 $992
Clonazepam Generic 82 $966
Mirtazapine Generic 61 $855
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 22 $782

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $5,881
$5,881 52 —
CAPLYTA
  • ITI, Inc. $183
$183 — —
LYBALVI
  • Alkermes, Inc. $122
$122 — —
ARISTADA
  • Alkermes, Inc. $59
$59 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record